$CI

Jones Nicole S sold $5.4M of CI

Jones Nicole S (See Remarks) sold 19,436 shares of Cigna Group (CI) at $276.27 ($5.37M total) on 2026-08-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jones Nicole S
Published Aug 6, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CI
Neutral
high confidence
Mentioned
$CI
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CINeutralLow
01

Why it matters

The newest concrete fact is the sale size ($5.37M) and execution details (19,436 shares at $276.27) with a pre-arranged plan, which generally reduces informational content about near-term business outlook.

02

Market read

Traders may note the filing for sentiment monitoring, but it is unlikely to drive a fundamental repricing without accompanying company-specific news.

03

What to watch

The article provides no context on total insider holdings beyond post-transaction shares, no reason for sale, and no follow-on purchases, limiting interpretability.

Relevance 5/10Novelty 3/10Timing: Filed 2026-08-06 for a sale executed 2026-08-04.

Background

The article is an SEC Form 4 insider transaction disclosure for Cigna Group, reporting an officer’s open-market sale executed under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$CINeutralHigh confidence
Context

Cigna Group Form 4 shows officer Jones Nicole S sold 19,436 shares at $276.27 on 2026-08-04 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move based solely on this filing.

Evidence & confidence

The filing is a routine insider transaction with an explicit 10b5-1 pre-arranged plan; it does not disclose new company performance, guidance, or regulatory developments.

Market effects

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or earnings changes.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, large dollar-value insider selling can still coincide with private views on risk or liquidity needs, so some traders may briefly fade the stock.

Key entities

  • Cigna Group

    CI, the company whose Form 4 insider sale is disclosed.

  • Jones Nicole S

    Officer who sold 19,436 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CIMed

The Cigna Group Hosts 2026 Investor Day; Introduces “Lead to One” to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities

Cigna Group (CI) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 The Cigna Group Hosts 2026 Investor Day; Introduces “Lead to One” to Drive Durable Growth Through Complex Care Leadership and Differentiated Capabilities • Following deliberate portfolio shaping over the last several years, The Cigna Group is strategically positioned

$NVOMed

GLP-1 prices are falling but a big change could affect what you pay

Novo Nordisk will cut U.S. list prices for Ozempic and Wegovy by 34% and 50% respectively, starting in 2027. Eli Lilly's new GLP-1 pill, Foundayo, was approved by the FDA. Prices vary by insurance coverage. Some employers, like PepsiCo and Cigna, are ending weight loss drug coverage. New drugs from Lilly, Novo Nordisk, and Amgen are in development.